Dialectical Behavior Therapy and Schema Therapy Show Similar Efficacy for BPD

Optimizing Psychotherapeutic Selection in Borderline Personality Disorder

Borderline personality disorder affects approximately 1.8 percent of the general population and up to 25 percent of psychiatric inpatients, presenting significant challenges in clinical management due to high risks of self-harm and suicide [1, 2]. While pharmacotherapy may address discrete comorbid symptoms like anxiety or mood instability, it has not demonstrated efficacy in reducing the core severity of the disorder [3]. Consequently, specialized psychotherapies have become the first-line standard of care, with dialectical behavior therapy and schema therapy emerging as two of the most frequently utilized evidence-based modalities [4, 5]. Despite their widespread use, clinicians have long lacked robust head-to-head data to determine if one specific approach offers superior long-term outcomes over the other [6]. A recent multicenter randomized clinical trial now provides a direct comparison of these two intensive interventions to clarify their relative effectiveness in outpatient settings.

Trial Design and Patient Demographics

The study was conducted as a 3-year multicenter superiority randomized clinical trial (a study design intended to determine if one treatment is more effective than another) between January 2019 and April 2025. This research was a component of the Borderline Optimal Treatment Selection (BOOTS) project, which aims to refine clinical decision-making for patients with borderline personality disorder. The trial took place across 9 Dutch outpatient centers, providing a broad clinical context for the findings. The researchers recruited individuals aged 18 to 65 years who met the diagnostic criteria for borderline personality disorder, ensuring the sample reflected the typical adult population seen in psychiatric practice. The study included a total of 204 participants, the majority of whom were female (172 female participants, or 84.3%). The cohort had a mean age of 32.21 years with a standard deviation of 9.57 years. Following recruitment, participants were allocated to one of two intensive psychotherapy arms using computerized covariate-adaptive randomization (a method that balances treatment groups based on specific participant characteristics), specifically accounting for sex and the severity of borderline personality disorder symptoms. Of the total sample, 95 participants (46.6%) were assigned to receive dialectical behavior therapy, while 109 participants (53.4%) were assigned to schema therapy. Both interventions were delivered over a two-year period using a combined group and individual format, allowing for a direct comparison of these two established therapeutic frameworks.

Comparing Intensive Treatment Modalities

The researchers implemented a rigorous protocol where both treatments were delivered over 2 years in a combined group-individual format, a structure designed to provide the intensive support often required for this patient population. To minimize bias, participants were randomized to dialectical behavior therapy or schema therapy via computerized covariate-adaptive randomization accounting for sex and BPD severity. This method ensures that the two treatment arms are balanced for key clinical and demographic variables from the outset. Furthermore, all assessments were administered by assessors blinded to treatment allocation, meaning the clinicians evaluating the patients did not know which therapy the individual had received, thereby protecting the objectivity of the data collection process. The primary outcome was the rate of change in DSM-5 BPD severity from baseline to 1-year posttreatment follow-up, which occurred 3 years after the initial baseline assessment. To quantify these changes, the study utilized the Borderline Personality Disorder Severity Index, fifth version (BPDSI-5) total score, a semi-structured clinical interview that measures the frequency and severity of the nine diagnostic criteria for the disorder. By focusing on the BPDSI-5, the researchers could track granular shifts in symptom clusters over the full three-year period, providing a longitudinal view of recovery that extends well beyond the active treatment phase. Beyond the primary measure of personality disorder severity, the trial tracked a wide array of secondary outcomes including DSM-5 BPD criteria, general symptom severity, functioning, quality of life, well-being, sleep problems, and treatment dropout. These metrics allow clinicians to understand the broader impact of these therapies on a patient's daily life and overall health. Monitoring dropout rates is particularly critical in this clinical context, as the intensive nature of these two-year programs often leads to significant attrition, which can complicate long-term management and resource allocation in outpatient psychiatric settings.

Long-Term Symptom Reduction and Clinical Outcomes

The primary intention-to-treat analysis (a statistical approach that includes all participants who were randomized, regardless of whether they completed the full treatment course) revealed no significant difference between dialectical behavior therapy and schema therapy in reducing borderline personality disorder severity (P = .27, r = 0.09). While the study was designed as a superiority trial to determine if one modality outperformed the other, the data indicated that both treatments resulted in large improvements in borderline personality disorder severity over the three-year study period. At the 36-month follow-up, which occurred one year after the active treatment phase concluded, the estimated mean difference between the two groups was only -1.09 on the Borderline Personality Disorder Severity Index, fifth version. This small difference was reflected in a Cohen d of 0.15 (a measure of effect size where 0.2 is typically considered small), with a 95% confidence interval of -0.17 to 0.47, suggesting that the clinical impact of choosing one therapy over the other is negligible in terms of overall symptom reduction. Beyond the primary metric of disorder severity, the researchers found that no significant differences between treatments were observed on any secondary outcome, including general psychiatric symptom severity, social functioning, quality of life, well-being, or sleep problems. Despite the lack of a superior modality, the clinical trajectory for patients in both arms was positive, as marked improvements over time were observed in both treatments for all secondary outcomes. These findings suggest that while dialectical behavior therapy and schema therapy utilize different theoretical frameworks and clinical techniques, they yield comparable long-term benefits for outpatients. For the practicing clinician, these results indicate that both intensive group-individual formats are effective options for achieving sustained symptomatic and functional gains in patients with borderline personality disorder.

Treatment Retention and Practical Implications

A critical consideration for clinicians managing borderline personality disorder is treatment adherence, particularly given the intensive two-year duration of these interventions. In this trial, dropout rates did not differ significantly between groups, suggesting that neither modality was inherently more difficult for patients to sustain than the other. For those randomized to dialectical behavior therapy, the dropout rate was 34% at the one-year mark and increased to 52% at the two-year mark. Similarly, participants in the schema therapy arm demonstrated comparable attrition, with a dropout rate of 29% at one year and 46% at two years. These figures highlight the persistent challenge of maintaining long-term engagement in high-intensity psychotherapy for this patient population, regardless of the specific therapeutic framework employed. For the practicing physician, these findings provide evidence that dialectical behavior therapy and schema therapy are equally viable options for the outpatient management of borderline personality disorder. Because there were no significant differences in symptom reduction, functional improvement, or treatment retention, the choice between these two evidence-based therapies can be individualized based on practical factors. Clinicians may reasonably base referrals on patient preference, the specific training and expertise of available local providers, or the specific clinical focus of each modality. While the overall attrition rate of approximately 50% by the end of the second year remains a clinical concern, the substantial improvements observed in those who remain in treatment underscore the value of both approaches in achieving long-term stabilization.

References

1. Leichsenring F, Fonagy P, Heim N, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024. doi:10.1002/wps.21156

2. Crotty K, Viswanathan M, Kennedy S, et al. Psychotherapies for the treatment of borderline personality disorder: A systematic review.. Journal of consulting and clinical psychology. 2024. doi:10.1037/ccp0000833

3. Lieb K, Vӧllm B, Rücker G, Timmer A, Stoffers‐Winterling J. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. The British Journal of Psychiatry. 2009. doi:10.1192/bjp.bp.108.062984

4. Hernandez-Bustamante M, Cjuno J, Hernández RM, Ponce-Meza JC. Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials.. Iranian journal of psychiatry. 2024. doi:10.18502/ijps.v19i1.14347

5. Santos LGD, Silva AFD, Bueno F, Cintra MA, Diniz NA, Bernardes CTV. Effects of psychotherapy and psychoanalytic-based approaches in the treatment of adults with Borderline Personality Disorder: a systematic review. 2026. doi:10.54033/cadpedv23n1-248

6. Setkowski K, Palantza C, Ballegooijen WV, et al. Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis. Psychological Medicine. 2023. doi:10.1017/s0033291723000685